Study to Evaluate the Efficacy of Afatinib in Skull Base Chordoma (NCT05519917) | Clinical Trial Compass
UnknownPhase 2
Study to Evaluate the Efficacy of Afatinib in Skull Base Chordoma
China20 participantsStarted 2022-10-01
Plain-language summary
This is a single arm, open label, single center, and prospective, interventional study to explore clinical efficacy of afatinib in patients with chordoma of skull base. Subject meeting the inclusion criteria will take afatinib (40 mg daily) orally, 4 weeks for a cycle. The primary objective is to assess the efficacy of afatinib in chordoma of skull base by objective response rate (ORR). The Secondary objectives is to assess progression free survival (PFS), overall survival (OS), tumor response duration and tumor shrinkage degree in patients with chordoma of skull base after using afatinib; to evaluate the safety and tolerability of afatinib in patients with chordoma of skull base.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients of 18 years and above;
* Patients with pathologically proven EGFR and/or HER2 expressing relapsed or residual chordoma of skull base, inappropriate or unwilling to receive surgery or radiotherapy;
* Adequate bone marrow function (Hb ≥ 6.0 mmol/L, absolute neutrophil count ≥ 1.5 x 109/L, platelets ≥ 75 x 109/L);
* An adequate renal function with GFR ≥ 45 ml/min calculated by Cockroft-Gault formula;
* Aspartate amino transferase (AST) or alanine amino transferase (ALT) ≤ 3 times ULN;
* Ability to swallow medication;
* Able to understand and provide written informed consent prior to any study procedures.
Exclusion Criteria:
* Life expectancy of less than 3 months;
* Known hypersensitivity to afatinib;
* Major surgery less than 4 weeks prior to start of the study;
* Patients who once participated in other clinical trials within 14 days before the initiation of the study;
* Systemic anti-cancer therapy within 28 days prior to start of the study;
* No tumor progression after radiation therapy prior to start of the study;
* History or presence of serious cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure NYHA classification of ≥ 3, unstable angina or poorly controlled arrhythmia, and myocardial infarction within 6 months prior to inclusion;
* Known pre-existing interstitial lung disease;
* No response after 2-week active treatment for known CTCAE Grade 3 or Grade 2 rash/acne;
* Any history or presence of poorly …